Patents by Inventor Xiaohui Du

Xiaohui Du has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210234447
    Abstract: An electric machine includes a machine rotor circumscribed by a machine stator, and having a rotor shaft, rotor stack, and end cap which rotate about an axis. The end cap includes lobes equal in number to a number of pole pairs of the machine rotor. A position sensor assembly has a predetermined alignment with the machine rotor and stator. The sensor assembly includes a sensor rotor formed by the lobes and a sensor stator having a printed circuit board with conductive sine and cosine traces. Machine rotor rotation causes the sensor assembly to output an unmodulated sine and cosine signals to a controller, which then calculates a calibrated reference angle. A magnetic axis of an electrical phase of the machine is aligned with and bisects a peak of the sine trace. A direct axis of the machine rotor aligns with an edge of a lobe.
    Type: Application
    Filed: January 28, 2020
    Publication date: July 29, 2021
    Applicant: GM GLOBAL TECHNOLOGY OPERATIONS LLC
    Inventors: Suresh Gopalakrishnan, Chandra S. Namuduri, Alexandru Rajala, Thomas W. Nehl, Xiaohui Du, Edward L. Kaiser
  • Publication number: 20210214387
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Application
    Filed: March 17, 2021
    Publication date: July 15, 2021
    Inventors: Xiaohui DU, John EKSTEROWICZ, Valeria R. FANTIN, Daqing SUN, Qiuping YE, Jared MOORE, Tatiana ZAVOROTINSKAYA, Brian R. BLANK, Yosup REW, Kejia WU, Liusheng ZHU, Johnny PHAM, Hiroyuki KAWAI, Chien-Hung YEH
  • Patent number: 11056943
    Abstract: A stator assembly includes a plurality of stator slots having multiple respective slot layers and a plurality of hairpins. The plurality of hairpins have a respective first leg positioned in one of the multiple respective slot layers and a respective second leg positioned in another of the multiple respective slot layers. A first set of n adjacent slots of the plurality of stator slots is configured to accommodate the plurality of hairpins carrying a current in a first phase, n being an integer. The plurality of hairpins is configured in respective conductor layers (L1, L2 . . . ) having a plurality of respective turn locations defining n respective turn positions. The plurality of hairpins is configured to occupy the n respective turn positions an equal number of times such that the respective conductor layers (L1, L2 . . . ) are electrically balanced.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: July 6, 2021
    Assignee: GM Global Technology Operations LLC
    Inventors: Khwaja M. Rahman, Xiaohui Du, Edward L. Kaiser
  • Patent number: 11046680
    Abstract: Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: June 29, 2021
    Assignee: AMGEN INC.
    Inventors: Ning Chen, Xiaoqi Chen, Yinhong Chen, Alan C. Cheng, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, James S. Harvey, Julie Anne Heath, Lars V. Heumann, Daniel B. Horne, Jonathan Houze, Matthew R. Kaller, Frank Kayser, Aarif Yusuf Khakoo, David J. Kopecky, Su-Jen Lai, Zhihua Ma, Julio C. Medina, Jeffrey T. Mihalic, Nobuko Nishimura, Steven H. Olson, Vatee Pattaropong, Gayathri Swaminath, Xiaodong Wang, Malgorzata Wanska, Kevin Yang, Wen-Chen Yeh
  • Patent number: 11028120
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: June 8, 2021
    Assignee: ORIC PHARMACEUTICALS, INC.
    Inventors: Xiaohui Du, John Eksterowicz, Valeria R. Fantin, Daqing Sun, Qiuping Ye, Jared Moore, Tatiana Zavorotinskaya, Brian R. Blank, Yosup Rew, Kejia Wu, Liusheng Zhu, Johnny Pham, Hiroyuki Kawai, Chien-Hung Yeh
  • Publication number: 20210130390
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Application
    Filed: December 8, 2020
    Publication date: May 6, 2021
    Inventors: Xiaohui DU, John EKSTEROWICZ, Valeria R. FANTIN, Daqing SUN, Qiuping YE, Jared MOORE, Tatiana ZAVOROTINSKAYA, Brian R. BLANK, Yosup REW, Kejia WU, Liusheng ZHU, Johnny PHAM, Hiroyuki KAWAI, Chien-Hung YEH
  • Publication number: 20210130389
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Application
    Filed: October 29, 2020
    Publication date: May 6, 2021
    Inventors: Xiaohui DU, John EKSTEROWICZ, Valeria R. FANTIN, Daqing SUN, Qiuping YE, Jared MOORE, Tatiana ZAVOROTINSKAYA, Brian R. BLANK, Yosup REW, Kejia WU, Liusheng ZHU, Johnny PHAM, Hiroyuki KAWAI, Chien-Hung YEH
  • Publication number: 20210122730
    Abstract: Described herein are glucocorticoid receptor modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.
    Type: Application
    Filed: April 10, 2018
    Publication date: April 29, 2021
    Inventors: Xiaohui DU, John EKSTEROWICZ, Valeria R. FANTIN, Yosup REW, Daqing SUN, Qiuping YE, Haiying ZHOU, Hiroyuki KAWAI, Jared MOORE, Johnny PHAM, Kejia WU, Liusheng ZHU, Dennis YAMASHITA
  • Publication number: 20210060000
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-assocaited conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Application
    Filed: March 13, 2020
    Publication date: March 4, 2021
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • Publication number: 20210047359
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Application
    Filed: October 23, 2020
    Publication date: February 18, 2021
    Inventors: Xiaohui Du, John Eksterowicz, Valeria R. Fantin, Daqing Sun, Qiuping Ye, Jared Moore, Tatiana Zavorotinskaya, Brian R. Blank, Yosup Rew, Kejia Wu, Liusheng Zhu, Johnny Pham, Hiroyuki Kawai
  • Publication number: 20210023095
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.
    Type: Application
    Filed: December 22, 2016
    Publication date: January 28, 2021
    Inventors: Daqing SUN, Lawrence R. MCGEE, Xiaohui DU, Liusheng ZHU, Xuelei YAN, Yosup REW, John EKSTEROWICZ, Julio C. MEDINA, Haiying ZHOU, Minna Delarae BALBAS, Valeria R. FANTIN
  • Publication number: 20210017220
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.
    Type: Application
    Filed: December 22, 2016
    Publication date: January 21, 2021
    Inventors: Daqing SUN, Lawrence R. MCGEE, Xiaohui DU, Liusheng ZHU, Xuelei YAN, Yosup REW, John EKSTEROWICZ, Julio C. MEDINA, Haiying ZHOU, Minna Delarae BALBAS, Valeria R. FANTIN
  • Publication number: 20210017219
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Application
    Filed: September 30, 2020
    Publication date: January 21, 2021
    Inventors: Daqing SUN, Lawrence R. McGEE, Xiaohui DU, Liusheng ZHU, Xuelei YAN, Yosup REW, John EKSTEROWICZ, Julio C. MEDINA, Valeria R. FANTIN, Haiying ZHOU, Minna Delarae BALBAS
  • Publication number: 20210002324
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.
    Type: Application
    Filed: December 22, 2016
    Publication date: January 7, 2021
    Inventors: Daqing SUN, Lawrence R. MCGEE, Xiaohui DU, Liusheng ZHU, Xuelei YAN, Yosup REW, John EKSTEROWICZ, Julio C. MEDINA, Haiying ZHOU, Minna Delarae BALBAS, Valeria R. FANTIN
  • Patent number: 10836789
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Grant
    Filed: June 1, 2020
    Date of Patent: November 17, 2020
    Assignee: ORIC PHARMACEUTICALS, INC.
    Inventors: Daqing Sun, Lawrence R. McGee, Xiaohui Du, Liusheng Zhu, Xuelei Yan, Yosup Rew, John Eksterowicz, Julio C. Medina, Valeria R. Fantin, Haiying Zhou, Minna Delarae Balbas
  • Publication number: 20200347090
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Application
    Filed: November 2, 2018
    Publication date: November 5, 2020
    Inventors: Xiaohui DU, John EKSTEROWICZ, Valeria R. FANTIN, Erica L. JACKSON, Daqing SUN, Qiuping YE, Jared MOORE, Tatiana ZAVOROTINSKAYA
  • Publication number: 20200291058
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Application
    Filed: June 1, 2020
    Publication date: September 17, 2020
    Inventors: Daqing SUN, Lawrence R. McGEE, Xiaohui DU, Liusheng ZHU, Xuelei YAN, Yosup REW, John EKSTEROWICZ, Julio C. MEDINA, Valeria R. FANTIN, Haiying ZHOU, Minna Delarae BALBAS
  • Patent number: 10736883
    Abstract: Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula (I) and Formula (II) have the following structures: (I); (II). Intermediates (V) are also claimed.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: August 11, 2020
    Assignee: AMGEN INC.
    Inventors: Matthew Brown, Ning Chen, Xiaoqi Chen, Yinhong Chen, Alan C. Cheng, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, James S. Harvey, Julie Anne Heath, Lars V. Heumann, Jonathan Houze, Frank Kayser, Aarif Yusuf Khakoo, David j. Kopecky, Su-Jen Lai, Zhihua Ma, Julio C. Medina, Jeffrey T. Mihalic, Steven H. Olson, Vatee Pattaropong, Gayathri Swaminath, Xiaodong Wang, Malgorzata Wanska, Wen-Chen Yeh
  • Patent number: 10723759
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: July 28, 2020
    Assignee: ORIC PHARMACEUTICALS, INC.
    Inventors: Daqing Sun, Lawrence R. McGee, Xiaohui Du, Liusheng Zhu, Xuelei Yan, Yosup Rew, John Eksterowicz, Julio C. Medina, Valeria R. Fantin, Haiying Zhou, Minna Delarae Balbas
  • Patent number: 10646482
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: May 12, 2020
    Assignee: FibroGen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du